Hills Bank & Trust Co Has $191,000 Position in Illumina, Inc. (NASDAQ:ILMN)

Hills Bank & Trust Co reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 35.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,429 shares of the life sciences company’s stock after selling 799 shares during the period. Hills Bank & Trust Co’s holdings in Illumina were worth $191,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bleakley Financial Group LLC acquired a new stake in Illumina during the 4th quarter worth about $751,000. Zacks Investment Management acquired a new stake in Illumina during the 3rd quarter worth about $2,924,000. Van ECK Associates Corp grew its holdings in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after acquiring an additional 22,718 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Illumina during the 4th quarter worth about $1,464,000. Finally, Allworth Financial LP grew its holdings in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after acquiring an additional 6,263 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $85.60 on Friday. Illumina, Inc. has a twelve month low of $80.18 and a twelve month high of $156.66. The stock’s 50 day moving average price is $113.52 and its 200-day moving average price is $129.88. The company has a market capitalization of $13.56 billion, a PE ratio of -11.15, a PEG ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ILMN. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Robert W. Baird reduced their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Citigroup reduced their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Piper Sandler raised their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.